Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Sandoz make history with 1st US biosimilar Zarxio

This article was originally published in Scrip

Executive Summary

Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).

Advertisement

Related Content

Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer/Celltrion Prep For October Inflectra Launch
Pfizer/Celltrion Prep For October Inflectra Launch
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Sandoz Climbs 'Pyramid' To Reach Biosimilar Success
Sandoz Climbs 'Pyramid' To Reach Biosimilar Success

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028018

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel